Search results

Selected filters:

Law & Policy
Analysis

Article type

Topic

Sector

Regions

Year

1,274 results found for your search

Sort options
28 January 2019

Critical condition: has Section 101 put the US medical device sector on life support?

As fears grow over subject-matter eligibility and technological convergence threatens to reshape the competitive landscape, patent strategy has become even more crucial for medical device companies

25 January 2019

Treat IP rights as property to maximise their value, Huawei CEO urges

In a rare public appearance, the Chinese telecom’s founder and CEO, Ren Zhengfei, reaffirms commitment to respect third-party patents and explains why paying more than the competition will keep his company ahead

25 January 2019

SCOTUS ruling is a blow to small companies on the frontline of life sciences innovation

The court’s decision in Helsinn Healthcare v Teva Pharmaceutical will disappoint the many biopharma businesses that depend on pre-marketing drug development collaboration

25 January 2019

New preliminary injunction rules set stage for Apple's showdown with Qualcomm

New rules on preliminary injunctions from the Supreme People's Court could have a significant affect on IP litigation in China – not least the long-running battle between Apple and Qualcomm.

24 January 2019

How <em>Arrow</em> declarations can target a clear path to market 

Given the difficulty that pharmaceutical products face when it comes to reaching market, Arrow declarations can be a crucial means of slicing through the knot.

22 January 2019

Despite its potential appeal to patent owners don’t expect a litigation stampede to Waco

Appointment of experienced patent litigator to local bench and Austin's growing reputation as a tech hub must be weighed against defendant-friendly rules

21 January 2019

New Indian patent office rules set to speed examinations

Draft changes would entitle women inventors and small businesses to expedited patent examination, but some see a backdoor for big business to take advantage too

18 January 2019

The clock is ticking as US government shutdown threatens to cause major pharma patent disruption

Services at the FDA could “grind to a halt” in a matter weeks if the budget deadlock between President Trump and Democrats continues. Major disruption at the USPTO and in the courts may also be on the cards.

18 January 2019

Downward trend in US patent litigation continues; Big Tech gets busier at the PTAB

Lawsuit filings and inter partes review petitions both fell in 2018, but operating companies’ share of the action was on the rise 

11 January 2019

Readiness to arbitrate with Huawei demonstrates InterDigital's FRAND intentions, CEO says

In exclusive interview with IAM, Bill Merritt claims that ADR can prevent current licence conflict with Huawei becoming a flashpoint in the US-China trade battle

10 January 2019

Iancu-inspired subject matter guidance meets with industry approval, but may make Congressional action less likely

After heavy trailing by the USPTO Director, agency proposes new details on issue of abstract ideas just as the Supreme Court turns its attention to “blockbuster” 101 Fed Circuit case

08 January 2019

Monsanto prevails in closely-watched Indian Supreme Court case

Reports say the top court upheld the patentability of novel genetically lab-engineered chemical entities like the company's blockbuster Bt cotton variety

04 January 2019

All the major China IP stories you missed over the holidays

Retrial ordered in Huawei v InterDigital; Apple representatives threatened with detention in continuing injunction flap; national IP appeals court opens doors and much more from the Middle Kingdom

04 January 2019

In licensing battle with Qualcomm, Apple is now in a very unfamiliar position

When it fought the smartphone wars, the iPhone giant was riding the crest of a sales wave; the current dispute, though, is being conducted as times get tougher

21 December 2018

Senator Hatch’s proposal to limit biopharma IPRs has come at the wrong time

Lame duck session attempt at reform looks likely to fail given recent changes at the PTAB and growing public concern over drugs pricing in the US